Tropisetron: An update of its use in the prevention of chemotherapy-induced nausea and vomiting

Drugs

Volumn 59, Issue 6, 2000, Pages 1297-1315

  Simpson, Kerryn ^a   Spencer, Caroline M ^a   McClellan, Karen J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALIZAPRIDE; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GRANISETRON; METOCLOPRAMIDE; ONDANSETRON; SEROTONIN 3 ANTAGONIST; TROPISETRON;

CHEMOTHERAPY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; HEADACHE; HUMAN; NAUSEA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REFRACTORY PERIOD; REVIEW; VOMITING;

EMESIS;

EID: 0034089129     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200059060-00008     Document Type: Review

References (71)

1. 1. Lee CR, Plosker GL, McTavish D. Tropisetron: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic. Drugs 1993 Nov; 46: 925-43
2. 3 receptor antagonists: differences and similarities. Eur J Cancer A 1997 Aug; 33: 1364-70
3. 3 receptor antagonists in antineoplastic therapy-induced emesis. Drug Saf 1998 Jan; 18: 43-56
4. 4 receptors of the release of 5-hydroxytryptamine from the guinea-pig small intestine. Naunyn Schmiedebergs Arch Pharmacol 1993 Feb; 347: 137-40
5. 5. de Bruijn KM. Tropisetron: a review of the clinical experience. Drugs 1992; 43 Suppl. 3: 11-22
6. 6. Fischer V, Baldeck J-P, Tse FLS. Pharmacokinetics and metabolism of the 5-hydroxytryptamine antagonist tropisetron after single oral doses in humans. Drug Metab Dispos 1992; 20 (4): 603-7
7. 7. Novartis Pharma AG. Navoban (tropisetron). Product monograph. Basel, Switzerland: Novartis Pharma AG, 1998
8. 3 receptor antagonist tropisetron in children. Pediatr Hematol Oncol 1996 Sep-Oct; 13: 405-16
9. 9. Wymenga ANM, van der Graaf WTA, Wils JA, et al. A randomized, double-blind, multicentre study comparing daily 2 and 5 mg of tropisetron for the control of nausea and vomiting induced by low-dose cisplatin-or non-cisplatin-containing chemotherapy. Ann Oncol 1996 Jul; 7: 505-10
10. 10. Yakushiji M, Tanaka H, Furue H, et al. Clinical phase II study of tropisetron capsule in the treatment of nausea and vomiting induced by anti-cancer drugs [in Japanese]. Gan to Kagaku Ryoho 1995 Jul; 22: 1073-86
11. 11. Van Belle SJP, Stamatakis L, Bleiberg H, et al. Dose-finding study of tropisetron in cisplatin-induced nausea and vomiting. Ann Oncol 1994; 5: 821-5
12. 12. Bruntsch U, Drechsler S, Eggert J, et al. Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents. Semin Oncol 1994 Oct; 21 Suppl. 9: 7-11
13. 13. Drechsler S, Bruntsch U, Eggert J, et al. Comparison of three tropisetron-containing antiemetic regimens in the prophylaxis of acute and delayed chemotherapy-induced emesis and nausea. Support Care Cancer 1997 Sep; 5: 387-95
14. 14. Sorbe B, Andersson H, Schmidt M, et al. Tropisetron (Navoban) in the prevention of chemotherapy-induced nausea and vomiting - the Nordic experience. Support Care Cancer 1994 Nov; 2: 393-9
15. 15. Falkson CI, Falkson HC. Antiemetic efficacy of tropisetron in patients failing previous antiemetic therapy. Oncology 1995; 52: 427-31
16. 16. Bleiberg H, Hulstaert F, Buyse M, et al. Tropisetron in the prevention of acute and delayed nausea and vomiting over six courses of emetogenic chemotherapy. Anticancer Drugs 1998 Oct; 9: 773-7
17. 17. The Nordic Antiemetic Trial Group, Sorbe BG, Högberg T, et al. Navoban (tropisetron) alone and in combination with dexamethasone in the prevention of chemotherapy-induced nausea and vomiting: the Nordic experience. Anticancer Drugs 1995 Feb; 6 Suppl. 1: 31-6
18. 3 antagonist prophylaxis is not maintained. J Clin Oncol 1996 Feb; 14: 644-51
19. 19. Chang T-C, Hsieh F, Lai C-H, et al. Comparison of the efficacy of tropisetron versus a metoclopramide cocktail based on the intensity of cisplatin-induced emesis. Cancer Chemother Pharmacol 1996 Jan; 37: 279-85
20. 20. Chua DTT, Sham JST, Au GKH, et al. The antiemetic efficacy of tropisetron plus dexamethasone as compared with conventional metoclopramide-dexamethasone combination in Orientals receiving cisplatin chemotherapy: a randomized crossover trial. Br J Clin Pharmacol 1996 May; 41: 403-8
21. 21. Lauria R, Palmieri G, Pepe R, et al. Comparison of tropisetron (ICS 205-930) with alizapride plus dexamethasone in the prevention of emesis induced by repeated cisplatin administration. Eur J Clin Res 1994; 5: 171-83
22. 3 antagonist, versus a standard antiemetic regimen of dexamethasone and metoclopramide in the treatment of cisplatin-containing chemotherapy. Drug Invest 1993 Sep; 6: 162-9
23. 3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis. Cancer 1994 Jan 15; 73: 445-54
24. 24. Anderson H, Thatcher N, Howell A, et al. Tropisetron compared with a metoclopramide-based regimen in the prevention of chemotherapy-induced nausea and vomiting. Eur J Cancer A 1994; 30A (5): 610-5
25. 25. Bruntsch U, Rüfenacht E, Parker I, et al. Tropisetron in the prevention of chemotherapy-induced nausea and vomiting in patients responding poorly to previous conventional antiemetic therapy. Ann Oncol 1993; 4 Suppl. 3: S25-29
26. 26. Jantunen IT, Kataja VV, Johansson RT. Ondansetron and tropisetron with dexamethasone in the prophylaxis of acute vomiting induced by non-cisplatin-containing chemotherapy. Acta Oncol 1992; 31 (5): 573-5
27. 27. Mantovani G, Macciò A, Bianchi A, et al. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial. Cancer 1996 Mar 1; 77: 941-8
28. 28. Marty M, Kleisbauer J-P, Fournel P, et al. Is Navoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induced emesis? Anticancer Drugs 1995 Feb; 6 Suppl. 1: 15-21
29. 29. Monda M, di Grazia M, De Vita F, et al. Tropisetron vs granisetron nell'emesi acuta e ritardata indotta da cis-platino: dati preliminari [in Italian, abstract]. Tumori 1994; 80 Suppl.: 150
30. 30. Zaluski J, Puistola U, Madej G, et al. Ondansetron plus dexamethasone, ondansetron and tropisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre, double-blind, randomised, parallel group study. Eur J Clin Res 1997; 9: 21-31
31. 31. Pin Z, Yan S, Honggang Z, et al. A randomized trial of tropisetron in the prophylaxis of nausea and vomiting induced by chemotherapy [in Chinese]. Chin J Oncol 1996; 18 (2): 154-6
32. 32. Campora E, Simoni C, Rosso R. Tropisetron versus ondansetron in the prevention and control of emesis in patients undergoing chemotherapy with FAC/FEC for metastatic or surgically treated breast cancer [in Italian]. Minerva Med 1994 Jan-Feb; 85: 25-31
33. 3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy - a randomised study. Eur J Cancer A 1993; 29A (12): 1669-72
34. 34. Yalçin S, Tekuzman G, Baltali E, et al. Serotonin receptor antagonists in prophylaxis of acute and delayed emesis induced by moderately emetogenic, single-day chemotherapy. Am J Clin Oncol 1999; 22 (1): 94-6
35. 3-receptor-antagonist in moderately emetogenic chemotherapy. J Chemother 1996 Jun; 8: 237-42
36. 3 receptors [abstract]. Ann Oncol 1994; 5 Suppl. 8: 204
37. 37. Garcia-del-Muro X, Vadell C, Pérez Manga G, et al. Randomised double-blind study comparing tropisetron alone and in combination with dexamethasone in the prevention of acute and delayed cisplatin-induced emesis. Eur J Cancer A 1998 Jan; 34: 193-5
38. 38. Adams M, Soukop M, Barley V, et al. Tropisetron alone or in combination with dexamethasone for the prevention and treatment of emesis induced by non-cisplatin chemotherapy: a randomized trial. Anticancer Drugs 1995 Aug; 6: 514-21
39. 39. Malik I, Moid I, Khan Z, et al. Prospective randomized comparison of tropisetron with and without dexamethasone against high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Am J Clin Oncol 1999; 22 (2): 126-30
40. 40. Sorbe BG, Berglind A-M, Andersson H, et al. A study evaluating the efficacy and tolerability of tropisetron in combination with dexamethasone in the prevention of delayed platinum-induced nausea and emesis. Cancer 1998 Sep 1; 83: 1022-32
41. 41. Van Belle SJP, Cocquyt VFJ, Bleiberg H, et al. Optimal combination therapy with Navoban (tropisetron) in patients with incomplete control of chemotherapy-induced nausea and vomiting. Anticancer Drugs 1995 Feb; 6 Suppl. 1: 22-30
42. 42. Schmidt M, Sorbe B, Högberg T, et al. Efficacy and tolerability of tropisetron and dexamethasone in the control of nausea and vomiting induced by cisplatin. Ann Oncol 1993; 4 Suppl. 3: S31-34
43. 43. Benoit Y, Hulstaert F, Vermylen C, et al. Control of nausea and vomiting by Navoban (tropisetron) in 131 children receiving cytotoxic chemotherapy. Anticancer Drugs 1995 Feb; 6 Suppl. 1: 9-14
44. 44. Berberoglu S. Prevention of emesis by tropisetron in children receiving combined chemotherapy with cisplatin. Pediatr Hematol Oncol 1995 Sep-Oct; 12: 479-83
45. 45. Cefalo G, Rottoli L, Armiraglio A, et al. Tropisetron (ICS 205-930) in pediatric oncology: first results in patients refractory to antiemetic metoclopramide-based treatments. Am J Pediatr Hematol Oncol 1994 Aug; 16: 242-5
46. 46. Gershanovich M, Kolygin B, Pirgach N. Tropisetron in the control of nausea and vomiting induced by combined cancer chemotherapy in children. Ann Oncol 1993; 4 Suppl. 3: S35-37
47. 47. Orten J, Hachimi-Idrissi S, Balduck N, et al. Prevention of emesis by tropisetron (Navoban) in children receiving cytotoxic therapy for solid malignancies. Semin Oncol 1994 Oct; 21 Suppl. 9: 17-9
48. 48. Rosso P, Cordero di Montezemolo L, Vivenza C, et al. Efficacy of tropisetron (Navoban) in controlling emesis induced in children by anti-cancer therapy. Tumori 1994 Dec 31; 80: 459-63
49. 49. Jiménez M, León P, Gimeno J, et al. A randomized comparison of intravenously administered chlorpromazine plus dexamethasone vs ondansetron vs tropisetron in the prevention of chemotherapy-induced emesis in children [abstract]. Pediatr Res 1997 Sep; 42: 399
50. 50. Stiakaki E, Savvas S, Lydaki E, et al. Efficacy of ondansetron and tropisetron in the control of nausea and vomiting induced by combined cancer chemotherapy in children [abstract]. Pediatr Res 1997 May; 41: 775
51. 51. Garbe C, Drechsler S, Fiedler H, et al. Dose comparison of tropisetron (Navoban) 5 mg and 10 mg orally in the prophylaxis of dacarbazine-induced nausea and emesis. Semin Oncol 1994 Oct; 21 Suppl. 9: 12-6
52. 52. Kobayashi K, Ishihara Y, Nukariya N, et al. Effects of antiemetic drug (tropisetron) on quality of life during chemotherapy: use of diary-type questionnaire and application of summary measures for assessment in a randomized, multicentre study. Respirology 1999; 4: 229-38
53. 53. de Bruijn KM. The development of tropisetron in its clinical perspective. Ann Oncol 1993; 4 Suppl. 3: S19-23
54. 54. Bateman DN, Rawlins MD, Simpson JM. Extrapyramidal reactions with metoclopramide. BMJ 1985 Oct 5; 291: 930-2
55. 55. Novartis. Navoban. Product Information. ABPI Compendium of Data Sheets and Summaries of Product Characteristics 1998-99. Datapharm Publications Limited, London
56. 56. Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidence-based clinical practice guidelines. J Clin Oncol 1999; 17: 2971-94
57. 57. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Prevention of chemotherapy-and radiotherapy-induced emesis: results of the Perugia Consensus Conference. Ann Oncol 1998; 9: 811-9
58. 58. Gralla RJ. Antiemetic therapy. Semin Oncol 1998 Oct; 25: 577-83
59. 59. Fauser AA, Fellhauer M, Hoffmann M, et al. Guidelines for anti-emetic therapy: acute emesis. Eur J Cancer 1998; 35 (3): 361-70
60. 60. Hainsworth JD, Hesketh PJ. Single-dose ondansetron for the prevention of cisplatin-induced emesis: efficacy results. Semin Oncol 1992; 19 (6 Suppl. 15): 14-9
61. 61. Italian Group for Antiemetic Research. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995; 332: 1-5
62. 62. Roila F, Tonato M, Cognetti F, et al. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 1991; 9: 674-8
63. 63. Duly SG, Friedman C, Yocum. K. Contribution of dexamethsone to antiemetic control with granisetron is greatest in patients at high risk of emesis [abstract]. Proc Am Soc Clin Oncol 1994; 13: 436
64. 64. Kris MG, Pendergrass KB, Navari RM, et al. Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone. J Clin Oncol 1997; 15: 2135-8
65. 65. Lofters WS, Pater JL, Zee B, et al. Phase III double-blind comparison of dolasetron mesylate and ondansetron and on evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol 1997; 15: 2966-73
66. 66. Peterson C, Hursti TJ, Börjeson S, et al. Single high-dose dexamethasone improves the effect of ondansetron on acute chemotherapy-induced nausea and vomiting but impairs the control of delayed symptoms. Support Care Cancer 1996; 4: 440-6
67. 67. Sekine I, Nishiwaki Y, Kakinuma R, et al. A randomized crossover trial of granisetron and dexamethasone versus granisetron alone: the role of dexamethasone on day 1 in the control of cisplatin-induced delayed emesis. Jpn J Clin Oncol 1996; 26: 164-8
68. 68. Silva RR, Basconi R, Giorgi F, et al. Granisetron plus dexamethasone in moderately emetogenic chemotherapy: evaluation of activity during three consecutive courses of chemotherapy. Support Care Cancer 1996; 4: 287-90
69. 69. Ruff P, Paska W, Goedhals L, et al. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. Oncology 1994; 5: 113-8
70. 70. Navari R, Gandara D, Hesketh P, et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 1995; 13: 1242-8
71. 71. Hesketh P, Navari R, Grote T, et al. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. J Clin Oncol 1996; 14: 2242-9